JP Morgan Upgrades Beam Therapeutics to Overweight, Raises Price Target to $40
Benzinga · 01/29 10:43
JP Morgan analyst Eric Joseph upgrades Beam Therapeutics (NASDAQ:BEAM) from Neutral to Overweight and raises the price target from $38 to $40.